Exploring the cytotoxic mechanisms of Pediocin PA-1 towards HeLa and HT29 cells by comparison to known bacteriocins: Microcin E492, enterocin heterodimer and Divercin V41. by Buss, G. et al.
Research Space
Journal article
Exploring the cytotoxic mechanisms of Pediocin PA-1 towards 
HeLa and HT29 cells by comparison to known bacteriocins












11 Exploring the cytotoxic mechanisms of Pediocin PA-1 towards HeLa and HT29 cells by 
12 comparison to  known bacteriocins.
13











25 1 Canterbury Christ Church University, N Holmes Road, Canterbury CT1 1QU
26 *Corresponding author
.CC-BY 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.07.443071doi: bioRxiv preprint 
2
27 Abstract
28 The purpose of this study was to explore potential mechanisms of cytotoxicity towards HeLa and
29  HT29 cells displayed by Pediocin PA-1. We did this by carrying out sequence alignments and 3D 
30 modelling of related bacteriocins which have been studied in greater detail: Microcin E492, 
31 Eneterocin AB heterodimer and Divercin V41. Microcin E492 interacts with Toll-Like Receptor 4 in 
32 order to activate an apoptosis reaction, sequence alignment showed a high homology between 
33 Pediocin PA-1 and Microcin E492 and 3D modelling showed Pediocin PA-1 interacting with TLR-4 in a 
34 way reminiscent of Microcin E492. Furthermore, Pediocin PA-1 had the highest homology with the 
35 Enterocin heterodimer, particularly chain A; Enterocin has also shown to cause an apoptotic 
36 response in cancer cells. Based on this we are led to strongly believe Pediocin PA-1 interacts with 
37 TLRs in order to cause cell death. If this is the case it would explain the difference in cytotoxicity 
38 towards HeLa over HT29 cells, due to difference in expression of particular TLRs. Overall, we believe 
39 Pediocin PA-1 exhibits a dual effect which is dose dependant, like that of Microcin. Unfortunately, 
40 the COVID-19 pandemic meant that we were unable to carry out experiments in the lab, and the 
41 unavailability of important data meant we were unable to make solid conclusions but rather 
42 suggestions. However despite this we have still been able to highlight interesting findings and how 
43 these could be translated into future research and therapeutics in order to improve the quality of 
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53 Introduction
54 From 2015-2017 there were around 367,000 people given a new diagnosis of cancer every year, with 
55 breast, prostate, lung and bowel cancer accounting for 53% of these new diagnosis’1. This study 
56 looks at the effect of Pediocin PA-1 on HT-29 cells, a cell line isolated in 1964 from colonic 
57 adenocarcinoma cells2; and HeLa cells, a cell line isolated in 1951 from cervical cancer cells3. 
58 Considering the neurotoxic effects of conventional therapies, such as chemotherapy and 
59 radiotherapy - from minor cognitive effects to major pathology such as encephalopathy4,5, the 
60 exploration of bacteriocins as a novel anti-cancer therapy allows the opportunity for a better quality 
61 of life for cancer patients undergoing treatment. Further still, targeted therapies have shown to 
62 improve the longevity and quality of patients lives6,7. Bacteriocins offer the opportunity for the 
63 development of highly targeted therapies whilst still ensuring an even greater quality of life. 
64 Pediocin PA1 is a 62-amino acid long class IIa bacteriocin expressed in Pediococcus acidilactiti (gram-
65 positive bacteria) generally in response to stress and/or ultraviolet light8,9. Bacteriocins are catatonic 
66 peptides produced by all types of bacteria that are non- immunogenic, biodegradable and can 
67 colonise cancer cells with specific toxicity10. Pediocin has been shown to display cytotoxic effects 
68 towards HeLa and HT29 cells, with a greater cytotoxic effect towards HeLa over HT2911. Whilst there 
69 have been several studies looking into the cytotoxic effect of Pediocin, the mechanism has never 
70 been studied in as great detail as other bacteriocins. This is a comparative study against other 
71 bacteriocins which have been researched in greater detail; it is hoped that by carrying out sequence 
72 alignments and 3D modelling we will be able to identify potential mechanisms of actions by Pediocin 
73 PA-1. Microcin E492 and Enterocin AB heterodimer have both been shown to induce apoptosis, 
74 indicating a protein interaction12,13,14. Therefore by comparing sequence alignment and analysing 3D 
75 models we hope  to identify similarities within the structure of Pediocin A1 compared to these 
76 bacteriocins which may give further insight into it’s mechanism of action. 
77 Furthermore, Divercin V41 is also a class IIa bacteriocin which was shown to have no cytotoxic effect 
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78 against HT29 – being of the same class of toxin as Pediocin PA-1 we hope to identify what is different 
79 between these two bacteriocins, and as such gain greater insight into Pediocin PA-1’s mechanism of 
80 action. 
81
82 There has been some controversy when it has come to the mechanism of Pediocin PA-1: four 
83 cysteine residues within the structure have been shown to form a disulphide bridge which forms a 
84 poration  complex in target membrane, leading to cell death15. It has also been found 
85 that Pediocin PA-1 is  able to function in the absence of protein receptors16. However, 
86 Enterocin has also been shown to cause permeabilization of the lipid bi-layer whilst also inducing 
87 apoptosis by bio-energetic collapse17 – this is indicative of protein interaction with 
88 Toll-Like Receptors (TLRs) to trigger a caspase response. Other bacteriocins have also been shown
89 to have this dual mechanism of cytotoxicity – which we discuss later in this paper. Therefore, we 
90 argue that it is likely Pediocin PA-1 also has a dual mechanism of cytotoxicity towards cancer 
91 cells.
92
93 Bacteriocins offer a potential advancement in the treatment of cancer, as most target cancer cells 
94 whilst having very limited interaction with human cells. This is due to the negative charge of cancer 
95 cells18 , the negative charge has been labelled the “Warburg Effect” which explains the 
96 secretion of more than thirty times the amount of lactic acid than healthy cells, by cancer cells19,20. 
97  Bacteriocins have an overall positive charge, and thus target cancer cells over human cells10.
98 Pediocin PA-1 itself is nontoxic, nonimmunogenic being used as a bio-food preservative 
99 protecting against Listeria monocytogenes21, other bacteriocins are also widely used in 
100 the same manner. In this way we know that Pediocin is safe for human consumption.
101
102 Whilst this study had it’s limitations due to the COVID-19 pandemic preventing us from carrying out 
103 in vitro experiments in the lab, we were still able to utilise bioinformatic tools to gain a further 
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104 insight into the potential mechanisms of Pediocin PA-1. Whilst also commenting on other
105 bacteriocins. In this way we were able to give a strong argument for further study, as well
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129 Methodology
130 Accessing Protein Sequences
131 UniProt was used to access the protein sequences in this analysis (see figure 1) ]. UniProt is an 
132 opensource database maintained by the UniProt consortium. The database is an amalgamation of 
133 Swiss-Prot, TrEMBL and the PIR Protein Sequence Database. It contains protein sequence and 
134 functional information often derived from primary genome research and analysis.
135 Pediocin PA1 and the other bacteriocins were located on the UniProt database, the PBD 3D structure 
136 was then downloaded. In the case of Divercin V41 there was no current PBD model, so the protein 
137 sequence was downloaded and modelled using Swiss Model23,24,25.
138 Sequence Alignment
139 Protein sequences were downloaded from UniProt and then aligned using MultiAlin22,26. Pediocin, 
140 Divercin, Microcin and Enterocin were uploaded to the server, default parameters of 90% high 
141 consensus and 50% low consensus were used. The sequence alignment was exported as a table 
142 image. 
143 Model Analysis
144 Once downloaded, PDB files were viewed in VMD27. VMD is an opensource modelling software 
145 which allows visualisation and analysis of protein structures. VMD can also be used to simulate and 
146 analyse the molecular dynamics of a system. We were able to use VMD to identify interacting 
147 residues that appeared significant to each protein structure and propose a mechanism of action 
148 based on this and previous in-vitro findings. It is worth noting that in the case of TLR-4 we located an 
149 accurate model of the LPS Ra complex of E. coli and TLR-4 interacting from RCSB PDB (named 3FXI). 
150 We then isolated the TLR-4 using the viewing toold of RCSB PDB and downloaded the .pdb file28.
151
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152 Swiss-model
153 Divercin V41 did not have a published PBD file on UniProt and we were unable to identify any 
154 previous research which had attempted to deduce the 3D structure. Therefore, we used Swiss-
155 Model to derive a predicted structure for Divercin V41, this was downloaded as a PBD file and 
156 viewed in VMD. We were also unable to locate a fully devised 3D structure for Enterocin B, so Swiss-
157 model was also used in this instance. SWISS-MODEL is an automated protein structure homology-





















Fig 1. Table showing the proteins analysed and 
their corresponding accession numbers as 
according to UniProt22.
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173 Results Microcin E492
174 Microcin E492 is a highly hydrophobic 7.9kDa bacteriocin produced by Klebsiella pneumonae30, 31. 
175 When co-cultured with HeLa cells cytotoxic effects observed were typical of apoptosis, these 
176 included: cell shrinkage, DNA fragmentation, caspase-3 activation and loss of mitochondrial 
177 membrane potential; cell necrosis was also observed at higher doses of Microcin13. Additionally the 
178 presence of zZAD-fmk (caspase inhibitor) completely blocked the cytotoxic effect of Microcin13. 
179 Caspase 3- activation is associated with the activation of toll-like receptor 4, therefore during the 3D 
180 modelling analysis we included toll-like receptor 4 (TLR-4) to observe how Microcin E492 interacts 
181 with it32.
182 Sequence Alignment
183 A sequence alignment was performed between Microcin E492 and Pediocin PA-1. Microcin E492 is a 
184 significantly larger protein than Pediocin, however despite this difference there is significant 
185 homology between the two proteins (See figure 2). Largely, the homology is of low consensus with 
186 only fourteen residues aligning with a high consensus.
187
188 3D Modelling: VMD
189 Unfortunately, despite extensive research there was no 3D model available for Microcin E492, 
190 therefore we used SWISS-MODEL to build a 3D model based on the fasta sequence obtained from 
191 RCSB PDB33. This was then downloaded as a .pdb file and viewed in VMD alongside the toll-like 
192 receptor-4. The model built using SWISS-MODEL had a sequence identity of 30%, whilst this is not 
193 ideal it is, to the best of our knowledge, the best model of Microcin E492 available at the time of 
194 research. 
Fig 2. Sequence comparison of  Microcin E492 and Pediocin A1 (Pediocin). Low consensus 
alignments (50%) are represented as blue letters, whilst high consensus alignments (90%) are 
represented as red letters. Microcin is significantly larger than Pediocin A1, whilst there is 
homology this a mainly low consensus homology with fourteen residues of high consensus26.
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195 TLR-4 is arranged as a heterodimer of two chains: A and B, they are arranged in a helical structure 
196 and the ends of each chain come fold around each other. According to VMD analysis (see figure 3), 
197 Microcin E492 sits in the middle of the heterodimer where both chains meet, interacting with both 
198 chains. Common contact residues for both chain A and B with Microcin included mainly hydrophobic 
199 residues: glycine, valine, phenylalanine, leucine and, isoleucine.
200 In order to explore the possibility that Pediocin PA-1 also could interact with TLR-4 we carried out 3D 
201 modelling of Pediocin PA-1 interacting with TLR-4 too (see figure 4). Whilst being smaller than 
202 Microcin E491, Pediocin also sat in between the receptor interacting with both chains as they met. 











Fig 4. 3D model of Pediocin A1 interacting with TLR-4 produced using the .pdb file 
imported from RCSB PDB to VMD. TLR-4 has been drawn in lines in order to distinguish 
between Pediocin A1 and TLR-4. Like Microcin, Pediocin appears mainly globular in 
shape, the TLR-4 is arranged as a heterodimer of two chains converging in the centre, 
Pediocin A1 interacts with both chains in the middle of this convergence27.
Fig 3. 3D model of Microcin (A) and Microcin interacting with TLR-4 (B) produced using 
the .pdb file imported from RCSB PDB to VMD. TLR-4 has been drawn in lines in order to 
distinguish between Microcin and TLR-4 A) Microcin appears mainly globular in shape 
and has small yet frequent regions of polarity. B) TLR-4 is arranged as a heterodimer of 
two chains converging in the centre, Microcin interacts with both chains in the middle of 
this convergence27.
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214 Results: Enterocin
215 Enterocin is a class IIa bacteriocin, it is a heterodimer formed from chains A and B and is produced by 
216 Enterococcus faecium. It is used within different food products due to it’s anti-listerial properties14, 
217 17. The heterodimer is formed by strong hydrophobic forces of leucine, isoleucine, tyrosine, glycine 
218 and phenylalanine residues34. Enterocin also displays cytotoxic effects towards HT29 and HeLa cells, 
219 as a heterodimer these effects were greater. Enterocin also displayed a greater effect towards HeLa 
220 than HT29 cells14. 
221 Sequence alignment and 3D models of Enterocin A and B were completed in order to distinguish 
222 whether there were any shared features between the mechanism of action of Pediocin and the 
223 Enterocin heterodimer. 
224
225 Sequence Alignment
226 A sequence alignment was carried out for PediocinA1, Enterocin A and, Enterocin B. The previous 
227 research has highlighted that Enterocin A and B potentially have different mechanisms of action, 
228 therefore by comparing Pediocin PA-1 to each homodimer it can give further insight into the exact 
229 mechanism of action of Pediocin PA-1. The highest homology is seen between Pediocin and 
230 Enterocin chain A, however there is still a significant homology between Pediocin and Enterocin B 
231 (see figure 5). This could indicate that Pediocin has a dual mechanism of action incorporating how 
232 Enterocin functions as a heterodimer. 
233
234
Fig 5. Sequence comparison of  Enterocin A (EntA), Enterocin B (EntB) and Pediocin A1 
(Pediocin). Low consensus alignments (50%) are represented as blue letters, whilst high 
consensus alignments (90%) are represented as red letters. Pediocin has a high level of 
alignment with both Enterocin A and Enterocin B26.
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235
236 3D Modelling Analysis
237 Enterocin A is significantly smaller than Enterocin B, 712 residues compared to 2125 residues. 
238 Enterocin B also appears to have a greater charged surface than Enterocin B. It is also interesting to 
239 note that both molecules have two cysteine residues (shown in yellow) on their surface (see figure 
240 7), however when acting as a homodimer these residues do not seem to be involved and there were 
241 no disulphide bridges detected on analysis. Further analysis revealed a hydrophobic surface of 
242 Enterocin, with exposed residues including: Val’15, Trp’33, Lys’43. Tyr’2, Trp’33 and Ala’32. This is in 














Fig 6. 3D model of Enterocin A produced using the .pdb file imported from 
RCSB PDB to VMD. A) shows the positive x/y axis angle of Enterocin A, 
whilst B) shows the negative x/y angle.  Analysis reveals regions of polar 
and charged residues (shown in red) of the surface of Enterocin B, as well 
as two cysteine residues (shown in yellow) on the surface of Enterocin A27. 
Fig 7. Devised 3D Model of Enterocin B alongside the Global Quality Estimate (C). 
Analysis reveals areas of polarity (A) and one cysteine residue (B). The overall sequence 
identity was 7.69% however, there is currently no 3D model of Enterocin B on it’s own, 
therefore this is the most accurate representation to date23, 24, 25.
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257 Divercin V41
258 Divercin has previously been shown to have a similar homology to Pediocin whilst showing no anti-
259 tumour properties towards HT29 cells36. Therefore we performed sequence alignment and 3D 
260 modelling of Divercin V41 in order to try and understand why, despite the similar homology, one 
261 shows anti-tumour effects towards HT29 cells and not the other.
262 The sequence comparison of Divercin V41 and Pediocin PA-1 shows a high homology, with high 
263 consensus (90% consensus) proteins including hydrophobic residues glycine and isoleucine; 
264 amphipathic residues tyrosine and tryptophan; and charged residues of glutamic acid (see figure 8). 
265 Charged residues of glutamic acid are often used in the formation of salt bridges. Low consensus 
266 proteins (50% consensus) include: hydrophobic residues glycine, isoleucine, alanine; charged 
267 residues lysine, aspartic acid, and lysine; polar charged residues histidine and glutamine. Polar 
268 charged residues are often associated with hydrogen bond formation through acting as protein 
269 donators and acceptors. 
270
271
272 The devised 3D model from SWISS MODEL (see figure 9) predicted Divercin V41 to be more linear in 
273 shape compared to Pediocin PA-1, which is more globular. Pediocin PA-1 is also shown to have a 
274 greater surface polarity than Divercin V41. Depending on the mechanism of action, both the 
275 difference in shape and polarity could go someway to explain why Divercin V41 does not show anti-
276 tumour effects on HT29 cells despite the relatively high homology with Pediocin PA-1.  
277
Fig 9. Devised 3D Models of Divercin V41 (B) and Pediocin A1 (A) alongside their Global 
Quality Estimate respectively (C and D). Pediocin is shown to have a greater surface 
polarity than Divercin. There is only a 37.50% sequence identity for the DIvercin V41 
model compared to the Pediocin A1 model, however due to the lack of data this is the 
most accurate model that we are aware of 23, 24, 25.
Fig 8. Sequence comparison of Divercin V41 and Pediocin A1 (shown as 
PPA1_PEDAC). Low consensus alignments (50%) are represented as blue 
letters, whilst high consensus alignments (90%) are represented as red 
letters. The overall consensus sequence is low alignment26.
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278 VMD analysis revealed exposed residues included charged residues: Asp’41, Lys’25, Lys’36 and 
279 Lys’65; polar residues: Asn’29, Asn’34, Gln’44, Gln’51, Tyr’2 and Tyr’32; hydrophobic residues: Gly’5, 
280 Gly’39 and Gly’64; as well as amphipathic Trp’42. There were also three Cysteine residues on the -y 


















Fig 3. 3D model of Divercin V41 produced using the .pdb file imported from SwissProt to VMD. A 
shows the positive x/y axis angle of Divercin V41, whilst B shows the negative x/y angle.  A 
analysis reveals regions of polar and charged residues (shown in red), whilst B reveals three 
cysteine residues (shown in yellow) (Humphrey, W., Dalke, A. and Schulten, K. 1996).
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299 Discussion
300 Like Pediocin PA-1, Microcin E492 has shown cytotoxic effects against HeLa cells. The observations of 
301 this cytotoxicity are inductive of apoptosis both biochemically and morphologically13. Further 
302 analysis revealed this apoptosis was due to caspase 1 and 3 activation. Definitive support can be 
303 found in the same study, as the use of zZad-fmk (a general caspase inhibitor) inhibited the cytotoxic 
304 effect of Microcin. Caspase 3 activation has been linked to the activation of TLR-436, therefore we are 
305 confident in our conclusion that Microcin must bind to TLR-4. Caspase 1 activation has been linked 
306 to the efflux of potassium ions, which activates the NLRC4 (nucleotide-binding oligomerization 
307 domain and leucine-rich repeat containing receptors) inflammasome pathway leading to the 
308 assembly of caspase 137. Considering that when high doses of Microcin E492 were administered to 
309 HeLa cells necrosis was observed13 , alongside the previously mentioned caspase-1 activation, and 
310 the link between programmed necrosis and membrane pore formation38. With this in mind, it is clear 
311 that microcin has a dual mechanism of apoptosis and pore-formation. 
312 Whilst Pediocin PA-1 is much smaller in size compared to Microcin E492, they are both globular in 
313 shape as well as having residues of similar properties. Furthermore, the 3D modelling analysis 
314 revealed that they also bind to TLR4 in the same manner. Pediocin PA-1 was showed to have a 
315 greater cytotoxic effect against HeLa cells compared to HT29 cells – however the researchers were 
316 only able to speculate11, if Pediocin PA-1 does interact with TLR-4 then one potential reason for this 
317 difference could be because TLR-4 is over-expressed in HeLa cells39. On the other hand, although 
318 TLR-4 is expressed in human colon cells, this appears to be mainly limited to crypt cells – alongside 
319 TLR-240 ; therefore, we would not expect as high levels of TLR-4 to be expressed in HT29 cells. This 
320 goes some way to explaining why we do not observe as extreme an effect in HT29 cells as we do in 
321 HeLa. 
322 We did consider the possibility of Pediocin PA-1 acting on other receptors, however due to the 
323 limitations of experimental data available, and the COVID-19 restrictions which prevented us from 
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324 carrying out lab work we were unable to effectively look at this. It would be interesting to explore 
325 the effect Pediocin PA-1 may have on TLR-2 – which has been shown to have a major role in TLR2 
326 recognition41. 
327 Divercin V41, like Pediocin PA-1, is produced from gram-positive bacteria; microcin however, is 
328 produced from gram-negative bacteria. Therefore, it would be interesting to explore how TLR-2 
329 expression effects cytotoxicity, especially considering its important role in the recognition of gram-
330 positive bacterial components. If Pediocin PA-1 does in fact interact with TLR-2, then this could go 
331 some way to explaining why Divercin, despite the high homology to Pediocin PA-1, does not display 
332 a cytotoxic effect to HT29 cells. Unfortunately, Divercin V41 has not been tested alongside HeLa 
333 (with high TLR-2/4 expression) and therefore it is difficult to compose more than a speculatory 
334 argument in regard to the mechanism. However, this observed difference in cytotoxicity despite high 
335 homology does give strong indication that Pediocin PA-1, like Microcin, has several cytotoxic effects 
336 which may be dose dependant. Going forward it would be interesting to carry out a comparative 
337 study on the cytotoxicity of Pediocin PA-1 and Divercin V41 in HeLa and HT29 cells of wild type, TLR-
338 2 knockout and TLR-4 knockout.
339 The Enterocin AB heterodimer has also been shown to be an apoptotic inducer of HeLa and HT29, 
340 which means it must also interact with a TLR, interestingly both homodimers of Enterocin induce an 
341 apoptosis however this effect is enhanced when acting as a heterodimer14. The study did not use 
342 caspase inhibitors or identify the caspase that induced apoptosis, therefore it is not possible to 
343 comment on what TLR Enterocin AB acts on, or whether they act on separate TLRs each – hence the 
344 enhanced effect when working as a heterodimer. Pediocin PA-1 and Enterocin A have the highest 
345 homology of all the compounds assessed and are the most similar in shape and structure. It is 
346 interesting then that inhibition of HeLa growth increased from 38..42% inhibition, when Enterocin B 
347 only was being used, to 78.83% growth inhibition when Enterocin A was added14. Both Pediocin PA-1 
348 and Enterocin A have cysteine residues, we know that in Pediocin PA-1 cystine residues lead to the 
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349 formation of two disulphide bonds which stabilise the hairpin conformation of the two beta sheets. 
350 Therefore, we believe it is from studying Enterocin A which will give us the best clues about the 
351 mechanism of action of Pediocin PA-1. A possible experiment could be to use TLR knockout HeLa 
352 cells alongside Enterocin A to observe the effect of inhibition, fluorescent microscopy could also be 
353 used to visualise the toxin with the cell. 
354 As well as evidence that Pediocin PA-1 induces apoptosis, it has been shown to target lipid vesicles 
355 as a dose dependant efflux of carboxyfluoerscein (CF). Imaging showed results were light scattering, 
356 meaning the lipid membrane was permeabilised but the overall structure was not changed15. Further 
357 support for this mechanism was seen when Pediocin PA-1 remained functional in the absence of 
358 protein receptors42, from this it was concluded that Pediocin did not interact with proteins, but 
359 rather was pore forming. We would argue that instead of this being Pediocin’s only mechanism of 
360 cytotoxicity, it is one of at least two. The toxins in this research are all class II bacteriocins, class II 
361 bacteriocins have all been recognised for their pore-forming mechanisms in bacteria43. However, as 
362 highlighted above many have been shown to cause bioenergetic collapse secondary to apoptosis, 
363 Microcin as an example was shown to cause apoptosis however at high doses, necrosis was 
364 observed. This clearly shows class IIa bacteriocins appear to have a dose dependant cytotoxic effect. 
365 We strongly feel that the findings of this study provide a strong argument and support for further, 
366 more targeted research into Pediocin PA-1 and other bacteriocins. With colon cancer expected to 
367 cause 52,980 deaths in the United States in 20211, and cervical cancer behind the cause of two 
368 deaths a day in the UK44, better treatment options need to be explored. With current conventional 
369 chemotherapy treatments causing significant central and peripheral neurotoxic effects4, bacteriocins 
370 such as those studied here offer the ability to target cancer cells whilst avoiding damage to other 
371 healthy human cells. By understanding the mechanism by which Pediocin PA-1 works, we can either 
372 isolate it for use in further studies and trials or derive a synthetic compound which works in a similar 
373 way.
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